The Impact of Absolute CD4 Count and Percentage Discordance on Pneumocystis Jirovecii Pneumonia Prophylaxis in HIV-Infected Patients
Current guidelines suggest that HIV-infected patients should receive chemoprophylaxis against Pneumocystis jirovecii pneumonia (PJP) if they have a cluster determinant 4 (CD4) count <200 cells/mm 3 or oropharyngeal candidiasis. Persons with CD4 percentage (CD4%) below 14% should also be considere...
Main Authors: | Henry Anyimadu MD, Chandra Pingili MD, Vel Sivapalan MD, Yael Hirsch-Moverman PhD, Sharon Mannheimer MD |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2018-03-01
|
Series: | Journal of the International Association of Providers of AIDS Care |
Online Access: | https://doi.org/10.1177/2325958218759199 |
Similar Items
-
Epidemiology of Pneumocystis jirovecii Pneumonia and (Non-)use of Prophylaxis
by: Albert Dunbar, et al.
Published: (2020-05-01) -
Nonadherence to primary prophylaxis against Pneumocystis jirovecii pneumonia.
by: James D Heffelfinger, et al.
Published: (2009-01-01) -
Pneumocystis jirovecii pneumonia prophylaxis for HIV-exposed neonates
by: Bennett NJ
Published: (2014-04-01) -
Pneumocystis jirovecii Pneumonia in Rheumatoid Arthritis Patients: Risks and Prophylaxis Recommendations
by: Shunsuke Mori, et al.
Published: (2015-09-01) -
Spelling Pneumocystis jirovecii
by: James R. Stringer, et al.
Published: (2009-03-01)